CLINICAL TRIALS PROFILE FOR CHLORMEZANONE

All Clinical Trials for chlormezanone

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02582736 ↗	Antipsychotics and Risk of Hyperglycemic Emergencies	Completed	Canadian Institutes of Health Research (CIHR)		2012-04-01	The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
NCT02582736 ↗	Antipsychotics and Risk of Hyperglycemic Emergencies	Completed	Drug Safety and Effectiveness Network, Canada		2012-04-01	The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
NCT02582736 ↗	Antipsychotics and Risk of Hyperglycemic Emergencies	Completed	Canadian Network for Observational Drug Effect Studies, CNODES		2012-04-01	The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.

Clinical Trial Conditions for chlormezanone

Condition Name

Condition Name for chlormezanone
Intervention	Trials
Psychotic Disorders	1
Schizoaffective Disorder	1
Schizophrenia	1
Bipolar Disorder	1

Condition MeSH

Condition MeSH for chlormezanone
Intervention	Trials
Mental Disorders	1
Emergencies	1
Disease	1
Diabetes Mellitus, Type 2	1

Clinical Trial Locations for chlormezanone

Trials by Country

Trials by Country for chlormezanone
Location	Trials
Canada	1

Clinical Trial Progress for chlormezanone

Clinical Trial Phase

Clinical Trial Phase for chlormezanone
Clinical Trial Phase	Trials

Clinical Trial Status

Clinical Trial Status for chlormezanone
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for chlormezanone

Sponsor Name

Sponsor Name for chlormezanone
Sponsor	Trials
Drug Safety and Effectiveness Network, Canada	1
Canadian Network for Observational Drug Effect Studies, CNODES	1
Canadian Institutes of Health Research (CIHR)	1

Sponsor Type

Sponsor Type for chlormezanone
Sponsor	Trials
Other	3

Last updated: April 30, 2026

Chlormezanone: Clinical Trials Update, Market Analysis, and Market Projections

What is chlormezanone and where is it used?

Chlormezanone is an oral muscle relaxant (skeletal muscle relaxant). It is marketed in multiple countries under brand formulations (commonly as tablets) and is positioned for short-term relief of painful musculoskeletal conditions, typically in settings that overlap with other centrally acting skeletal muscle relaxants.

What is the clinical trial status of chlormezanone?

No complete, audit-ready trial landscape can be produced from the provided information. A “clinical trials update” requires verified trial identifiers (e.g., NCT/EudraCT), study phases, enrollment status, endpoints, sponsor details, and dates. Without those inputs, a complete and accurate update cannot be delivered.

How is the market structured for chlormezanone?

A defensible market analysis also requires current market-size sources tied to geography and product form (brand vs generic), plus prescribing or reimbursement signals. Those inputs are not present, so a complete and accurate market characterization cannot be produced.

What market projections can be made?

Reliable projections need a baseline market size, growth drivers (incidence of back pain, uptake of muscle relaxants, guideline changes), supply constraints (patent/generic timeline), and pricing dynamics by country. None of those required inputs are provided.

Key Takeaways

No complete and accurate clinical trials update, market analysis, or market projection can be produced for chlormezanone from the information available in this request.

FAQs

1) Is chlormezanone still actively developed in clinical trials?
A verifiable answer requires trial registries (NCT/EudraCT) and study timelines. Those are not provided.

2) Which indications are chlormezanone trials targeting?
Indications must be confirmed from protocol documents or trial registry entries. Not available here.

3) How large is the global market for chlormezanone?
Market size requires region-by-region revenue or unit estimates from cited datasets. Not available.

4) Will generics likely drive pricing pressure?
Generic impact depends on patent status and local regulatory timelines, which are not provided.

5) What is the realistic revenue outlook for chlormezanone over the next 5 to 10 years?
Forward projections require a baseline market, growth assumptions, and competitive landscape with dated evidence. Not available.

References

No sources were cited because no auditable clinical, regulatory, or market data were provided.